Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD

Despite an expanding treatment landscape, ulcerative colitis (UC) remains a challenging chronic condition for many patients, particularly those with moderate to severe disease who fail multiple lines of therapy. The need for new, effective, and better-tolerated options continues to drive innovation in the field.

American College of Gastroenterology (ACG)’s 2025 Annual Scientific Meeting

, attention turned to obefazimod, a first-in-class small molecule with a novel, non-immunosuppressive mechanism of action. Data from a pair of phase 3 studies, ABTECT 1 and ABTECT 2, were presented during a late-breaking session at ACG by Bruce Sands, MD, Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at the Mount Sinai Medical Center and the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and shed further light on the treatment’s potential in UC.

“Obefazimob is a small molecule that promotes micro RNA 124, so it enhances micro RNA 124 expression, which then downregulates a number of pro-inflammatory signals within cells,” Sands explained to 

. “It is not immune suppressing, it actually just sort of regulates and normalizes the signals.”

ABTECT-1 and ABTECT-2 are global, multicenter, randomized, double-blind, placebo-controlled trials assessing once-daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active UC. Eligible participants had inadequate response, loss of response, or intolerance to conventional and/or advanced therapies.

The trials were conducted simultaneously and have enrolled patients from > 600 participating clinical trial sites in 36 countries with the intent to satisfy regulatory requirements globally. As described by parent company Abivax, the ABTECT program is one of the largest phase 3 UC trials ever conducted and includes the largest population of patients with inadequate response to JAK inhibitor therapy.

A total of 1272 patients were randomized and treated in ABTECT-1 (n = 636) and ABTECT-2 (n = 636). In both trials, baseline demographics and disease characteristics were similar between groups; 45.3% and 49.3% of patients had inadequate response to ≥ 1 advanced therapy.

In both trials, a significantly higher proportion of patients receiving obefazimod 50 mg achieved clinical remission and all key secondary endpoints versus placebo. In ABTECT-1, but not ABTECT-2, a significantly higher proportion of patients receiving obefazimod 25 mg achieved clinical remission and all key secondary endpoints. In a pooled analysis, both obefazimod 50 mg and 25 mg met all primary and secondary endpoints with nominal significance.

The rate of serious adverse events and treatment emergent adverse events (TEAEs) leading to study drug discontinuation for obefazimod-treated patients were similar to placebo. Investigators noted proportions of patients who reported ≥ 1 TEAE were greater for obefazimod 50 mg and similar for obefazimod 25 mg versus placebo in both trials, with headache being the most frequent TEAE.

“The exciting thing is that obefazimod is oral. It's once daily, so it's convenient. It's a small molecule, so it won't be immunogenic as some biologics can be, and this is an entirely new mechanism of action, so it's exciting to see that it may work in ulcerative colitis,” Sands said.

Editors’ Note: Sands reports relevant disclosures with AbbVie, Alimentiv, Amgen, Bristol Myers Squibb, AstraZeneca, Ferring, and others.

Sands BE, Danese S, Peyrin-Biroulet L, et al. Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT 1 & 2) (Late-Breaking Abstract). Presented at the American College of Gastroenterology (ACG)’s 2025 Annual Scientific Meeting. Phoenix, Arizona. October 27-29, 2025.

Brooks A. Obefazimod Meets Primary Endpoint in Phase 3 ABECT Program for Ulcerative Colitis. HCPLive. July 23, 2025. Accessed November 13, 2025. 

https://www.hcplive.com/view/obefazimod-meets-primary-endpoint-phase-3-abect-program-ulcerative-colitis

Videos

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

Discussing Findings on Secukinumab (Cosentyx) Efficacy Over 4 Years in HS, With Martina Porter, MD

New late-breaking, phase 3 data have been released demonstrating secukinumab’s (Cosentyx) efficacy over 4 years in patients with hidradenitis suppurativa (HS).

These new post-hoc analysis findings were presented during the 10th annual Symposium on Hidradenitis Suppurativa Advances (SHSA). 

 spoke about the findings with Martina J. Porter, MD, a trial investigator, assistant professor of dermatology at Harvard Medical School, and vice chair for research and academics at Beth Israel Deaconess Medical Center.

“You've seen the data from the core trials that led to the FDA approval, and we have shown the Week 104 data as well, but now we're getting data all the way out to Week 204,” Porter said. “So, this is the longest, long-term extension data that we have now for any IL-17 inhibitor in HS, and it's really impactful and reassuring, both from a safety and efficacy perspective. Also, I think it reinforces what we've talked about before, that IL-17 really doesn't have immunogenicity, and so patients tend to maintain their response for many years.”

Porter highlighted details of the post-hoc analysis, noting patients with moderate to severe HS were evaluated previously in the SUNSHINE and SUNRISE core and extension trials. Those who had attained a clinical response at the 52-week mark (HiSCR responders) were included. These findings, Porter highlighted, show the evolution of clinical response up to the 204-week mark

Clinical response was evaluated by Porter and coauthors as a reduction of 50% (HiSCR50), 75% (HiSCR75), 90% (HiSCR90), or 100% (HiSCR100) in study participants’ total number of inflammatory abscesses and nodules. The investigators found, among HiSCR responders at the 52-week mark, 81.3% sustained HiSCR50 between 1 and 4 years. Also, Porter et al found in that same timeframe, 72.9%, 46.9%, and 35.4% of those assessed improved their response to secukinumab from HiSCR50 to HiSCR75, HiSCR90, and HiSCR100, respectively.

“So it's very good,” Porter explained. “The safety data was very in line with secukinumab’s known safety profile for all its other indications, even though this is the highest dose of secukinumab used for any indication. I think that's very reassuring. So nothing exciting, fortunately, in the safety data. And compared to the other IL-17 inhibitors that are approved for HS, like bimekizumab, there are relatively low rates of fungal infections, hypersensitivities, or rashes in the secukinumab patients out to 4 years.”

Porter also highlighted secukinumab treatment’s impact on draining tunnels, which the investigative team had found saw a notable decrease of 68.5% in draining tunnels maintained by patients treated with the medication. Overall, secukinumab was well-tolerated and had a strong safety profile, consistent with previously shared data.

“The safety profile of secukinumab long term is probably better than bimekizumab, if you look at the percentages of some of the adverse reactions that we commonly associate with IL-17 inhibitors…” Porter said. “But I think when we talk about shared decision making with patients, it helps to guide management, because I have different groups of patients who are really looking for immediate efficacy results versus mostly choosing the absolutely safest drug they can. So I think having this long-term data can really help guide those decisions.”

For any additional information on these findings on secukinumab in patients with HS, view the full interview posted above.

The quotes contained in this summary were edited for clarity.

Kimball AB, Bechara FG, Alavi A, et al. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial. Br J Dermatol. 2025 Mar 18;192(4):629-640. 

Kunzmann K. FDA Approves Secukinumab for Hidradenitis Suppurativa. HCPLive. November 1, 2023. Accessed November 13, 2025. 

https://www.hcplive.com/view/fda-approves-secukinumab-hidradenitis-suppurativa

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

James Tumlin, MD, is the president of NephroNet, director of research at Georgia Nephrology, and a professor of medicine in nephrology at Emory University School of Medicine.

Povetacicept Data Validate APRIL/BAFF Inhibition in IgAN and pMN, With James Tumlin, MD

Povetacicept led to substantial, sustained UPCR reductions with stable eGFR, significant Gd-IgA1 reductions, hematuria resolution, clinical remission, with favorable safety in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN).

These findings, from the phase 1/2 RUBY-3 trial, were presented at the 

American Society of Nephrology (ASN) Kidney Week 2025

, held November 5-9, 2025, in Houston, Texas, by James Tumlin, MD, Adjunct Professor, Department of Medicine, Emory University School of Medicine.

Povetacicept is designed to simultaneously inhibit BAFF and APRIL, two central cytokines that regulate pathogenic B-cell maturation, immunoglobulin class switching, plasma-cell survival, and downstream autoantibody production. Unlike agents that act downstream on inflammation or proteinuria, this approach aims to directly interrupt the causal biology driving Gd-IgA1 generation in IgAN and anti-PLA2R autoantibody production in pMN. The 48-week analyses from RUBY-3 provide the clearest evidence to date that these upstream immunologic effects translate into meaningful reductions in proteinuria and support the potential for disease-modifying impact.

Patients with IgAN receiving povetacicept 80 mg experienced a 64% mean reduction in 24-hour UPCR at week 48, with 65% achieving UPCR <0.5 g/g, stable eGFR, and early, deep, and sustained declines in circulating Gd-IgA1 (77% by week 48). Hematuria resolved in 90% and more than half reached clinical remission. In people with pMN, the same dose achieved an 82% reduction in UPCR, durable stabilization of kidney function, and 83% reductions in anti-PLA2R autoantibodies, with 100% of patients in immunologic remission and universal achievement of partial remission.

 spoke with Tumlin to discuss how dual BAFF/APRIL inhibition reshapes disease biology in IgAN and pMN, what the 48-week kinetics suggest about long-term remission potential, and how these findings may influence future treatment sequencing in immune-complex glomerular disease.

Across both diseases, povetacicept was generally well tolerated, with decreases in IgG monitored but not associated with serious infections or clinically significant immune compromise. Tumlin emphasized that these characteristics underscore its promise as a disease-modifying therapy, distinct from hemodynamic or anti-proteinuric approaches.

"I think, looking forward ahead, the APRIL/BAFFS may be able to induce a more long and sustained remission. Don't know that yet, but that's data that will be evolved and gleaned out over time," Tumlin said.

Disclosures for Tumlin include Vera Therapeutics, Calliditas Therapeutics, Alexios Pharmaceuticals, and Vertex Pharmaceuticals.

Tumlin JA, Yalavarthy R, Kim DK, et al. Efficacy and Safety of Povetacicept in Patients with IgAN and Primary Membranous Nephropathy (pMN) at 48 Weeks of Treatment: The RUBY-3 Study. Presented at: ASN Kidney Week. Houston, Texas. November 05-09, 2025. #SA-OR091

Tumlin discussed improvements in UPCR and Gd-IgA1 seen with povetacicept.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

an internal medicine and pediatrics-trained allergist practicing in Mobile, Alabama.

Tapinarof Shows Early, Sustained Benefits in Pediatric Atopic Dermatitis, With Druhan Howell, MD

New findings from a subanalysis of the phase 3 ADORING 1 and ADORING 2 trials demonstrated the efficacy and safety of 1% tapinarof (VTAMA) cream in pediatric patients with

2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

 in Orlando, Florida, investigator Druhan Howell, MD, an internal medicine and pediatrics-trained allergist practicing in Mobile, Alabama, reviewed the clinical significance of these results for everyday practice.

“A lot of the patients that we are seeing in clinical practice have more than one thing going on in the allergic world, so they'll have atopic dermatitis, allergic rhinitis, and asthma,” Howell said. “What we saw in the sub-analysis was that these patients had the same clinical improvement as patients who only had atopic dermatitis, which is important so that we know that when we are treating all of these patients, they will see the same sort of results.”

Tapinarof, an aryl hydrocarbon receptor (AhR) agonist, works by restoring skin barrier homeostasis, decreasing inflammation, and reducing oxidative stress—mechanistic features that distinguish it from existing topical options. The US Food & Drug Administration (FDA) approved this drug in December 2024 for adults and children aged ≥ 2 years with AD.

The pooled subanalysis evaluated 654 children aged 2 – 17 years with moderate to severe AD, including those with comorbid allergic conditions, such as asthma, allergic rhinitis, and food allergies. The data revealed early and sustained improvements in key clinical and patient-reported outcomes, regardless of comorbidity status.

By week 1, children treated with tapinarof cream showed measurable improvements in skin clearance and appearance, with vIGA-AD™ response rates of 42.3% in those with comorbidities and 49.5% in those without (

 <.0001). These effects persisted through week 8. Improvements in eczema severity, measured by EASI-75, were seen as early as week 2 and maintained through week 8 (54.5% with comorbidities vs. 21.8% with vehicle; 63.1% without comorbidities vs. 20.4% with vehicle; 

Patient-reported outcomes followed a similar pattern. Sleep and overall symptom burden, measured by POEM scores, improved significantly by week 1 and continued through week 8. Children also experienced meaningful itch reduction, with ≥ 4-point improvements on the Peak Pruritus–Numeric Rating Scale (PP-NRS) at week 2 (55.6% with comorbidities vs. 36.3% with vehicle; 63.3% without comorbidities vs. 29.2% with vehicle).

Investigators observed no new safety signals in the pediatric subgroup. The most common treatment-emergent adverse events included folliculitis (7.8%), upper respiratory tract infection (4.6%), and headache (3.7%).

“VTAMA is a new and novel mechanism of action. The aryl hydrocarbon receptor agonist goes in, and it is really leading to homeostasis and a disrupted skin barrier, so it improves the skin barrier, it decreases inflammation, and it decreases oxidative stress, all of which lead to improvement of the skin,” Howell said. “That really is new in the atopic dermatitis space. It’s nice to have something new and different to provide to our patients.”

Reported disclosures for Howell include Dermavant Sciences, Inc., AstraZeneca Pharmaceuticals LP, Actelion Pharmaceuticals US, Inc., GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., CSL Behring, Takeda Pharmaceuticals U.S.A., Inc., Blueprint Medicines Corporation, Amgen Inc., Philips North America LLC, Pulmonx Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Grifols USA, LLC, Baxter Healthcare, Vifor Pharma, Inc., Mylan Specialty L.P., and 

Howell D. Sub-analysis of pooled data from its ADORING 1 and ADORING 2 clinical trials demonstrating early and consistent response to VTAMA® (tapinarof) cream, 1%, across key measures, regardless of comorbidity status, in children aged 2-17 years with atopic dermatitis (AD). Presented at ACAAI in Orlando, Florida, from November 6 – November 10, 2025.

New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities | Organon. Organon. Published November 13, 2025. Accessed November 13, 2025. https://www.organon.com/news/new-data-show-early-and-consistent-response-to-vtama-tapinarof-cream-1-in-children-aged-2-with-atopic-dermatitis-including-those-with-associated-comorbidities/

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist and director of the Houston Research Institute.

Once a disease with no approved pharmacologic treatment options, the therapeutic landscape for metabolic dysfunction-associated steatohepatitis (MASH) has undergone rapid, unprecedented progress in recent years.

Sparked by the US Food and Drug Administration approval of resmetirom (Rezdiffra) in 2024 and semaglutide (Wegovy)’s 2025 approval, the MASH treatment armamentarium has greatly expanded and is expecting even more additions as more and more agents continue to progress through clinical development and show promise in trials.

Among these is pemvidutide, a balanced (1:1) GLP-1/glucagon dual receptor agonist in development for the treatment of MASH, alcohol use disorder, and alcohol-associated liver disease. Its use in biopsy-confirmed MASH and fibrosis stage F2 or F3 was assessed in the phase 2, randomized, placebo-controlled, double-blind IMPACT trial. Results of the primary analyses of the study at 24 weeks of treatment were presented at the 

American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025

 by Mazen Noureddin, MD, MHSc, a professor of medicine at Houston Methodist Hospital and co-chairman of Summit Clinical Research’s Board of Directors.

In the trial, 212 patients were randomly assigned in a 1:2:2 ratio to receive once-weekly subcutaneous pemvidutide 1.2 mg or 1.8 mg administered without dose titration, or placebo. The dual primary endpoints were MASH resolution without worsening of fibrosis or ≥1 stage liver fibrosis improvement without worsening of MASH at 24 weeks.

Among the cohort, the mean age was 53 years, the mean BMI was 39 kg/m2, 58% of patients were female, and 43% had type 2 diabetes. MASH resolution without fibrosis worsening was observed in 18 (20%) of 86 patients in the placebo group, 24 (58%) of 41 patients in the pemvidutide 1.2 mg group (95% CI, 21 to 56; 

<.0001), and 45 (52%) of 85 patients in the pemvidutide 1.8 mg group (95% CI, 19 to 46; 

Fibrosis improvement without worsening of MASH was observed in 24 (28%) of 86 patients in the placebo group, 13 (33%) of 41 patients in the pemvidutide 1.2 mg group (95% CI, -13 to 22; 

= .59), and 30 (36%) of 85 patients in the pemvidutide 1.8 mg group (95% CI, -6 to 22; 

= .27). Additional AI-based analyses of the liver biopsies and non-invasive tests for MASH and fibrosis were statistically significant at both pemvidutide doses, consistent with an ongoing anti-fibrotic effect.

Mean weight losses were 0.5% in the placebo group compared with 4.8% (

<.001) in the 1.8 mg group. Pemvidutide was well-tolerated despite the absence of dose titration, with discontinuations due to adverse events of 2%, 0%, and 1%, in the placebo, 1.2 mg, and 1.8 mg groups, respectively.

For additional insight into pemvidutide and the IMPACT data presented at AASLD, the editorial team of 

 spoke with Noureddin for the following Q&A:

Can you explain a little bit about pemvidutide and why we think it may be promising not only for MASH, but also alcohol use disorder and alcohol-associated liver disease?

Pemvidutide is a glucagon GLP-1, and the ratio is very attractive because it's one to one. It also does have a special PK property that makes it safe and well tolerated. They modified it in a way that it has delayed Tmax and lower Cmax, which makes it completely tolerable, especially with the formula that they have. So in terms of MASH, the glucagon has a direct effect on the liver, so as for ALD. What that does is a strong anti-fibrotic effect, and in addition to reducing steatosis, inflammation, and fibrosis in this patient population because of the dual property, especially with the glucagon, in alcohol, it can also decrease the craving via central effect. So it's an attractive drug for all steatotic liver disease in that perspective.

What were some of the key findings from IMPACT you presented here at AASLD?

This is a 48 week study, but what we at AASLD presented is 24 weeks, which is the primary endpoint and the histology. We had histology before and after, and we randomized participants to placebo versus 1.2 milligrams versus 1.8 milligrams. There was no titration, which is very important for this drug because all other glucagon GLP-1s titrate.

Patients went on it and had multiple other NITs, PDFF, VCTE, and we also looked at weight loss. Primary inclusion criteria was MASH and F2 and F3, PDFF 8%, BMI of 27, and we did biopsy before and after.

The primary endpoint was met on the MASH resolution. It's actually on the higher side, it was up to 58% of the population at week 24. For fibrosis, we had a change of magnitude of 38%, but we had a high placebo rate, so no statistical significance. However, when we did better methodology for assessing fibrosis, which is AI, it was statistically significant all the way around and all the NITs were also positive, so that was good. Importantly, there was statistical significance on weight loss by week 24, so this is the first glucagon GLP-1 that leads to both histological improvement as well as weight loss at week 24.

The safety signal actually is a big differentiator for this drug. As a reminder, there’s no titration. The discontinuation rate due to adverse events was almost nothing. We had 1 patient on the higher dose and there were 2 patients on placebo, so we had more people stop due to AEs in the placebo than the drug. It's a very clean drug in terms of side effects.

I think it looks like discontinuation and the weight loss and NITs at 24 weeks are heading in the right direction. The plan to do it is for a longer duration where we think we're going to get more fibrosis and more weight loss in this patient population.

Editors’ Note: Noureddin reports relevant disclosures with Gilead, GlaxoSmithKline, Madrigal, Novo Nordisk, Takeda, 89BIO, Altimmune, Boehringer Ingelheim, and others.

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed November 13, 2025. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed November 13, 2025. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Noureddin M, Harrison S, Loomba R, et al. A Phase 2, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis. Presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. Washington, DC. November 7-11, 2025.

Articles

The therapeutic landscape for metabolic dysfunction-associated steatohepatitis (MASH) has significantly evolved with the FDA approvals of resmetirom and semaglutide. Pemvidutide, a GLP-1/glucagon dual receptor agonist, shows promise in treating MASH, alcohol use disorder, and alcohol-associated liver disease. The phase 2 IMPACT trial demonstrated significant MASH resolution and weight loss with pemvidutide, although fibrosis improvement lacked statistical significance. Pemvidutide was well-tolerated, with minimal adverse events. The drug's unique pharmacokinetics and dual action make it a promising candidate for various steatotic liver diseases.

Noureddin explains 24-week data showing significant MASH resolution, weight loss, and evidence of anti-fibrotic activity with the GLP-1/glucagon dual receptor agonist.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

IMPACT: Pemvidutide for MASH Resolution and Weight Loss, With Mazen Noureddin, MD, MHSc

Matthew R. Weir, MD is an attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital.

Weir pointed out that significant benefits were seen with concurrent SGLT2 inhibitor use.

Chronic Kidney Disease

Beyond Hypertension: Lorundrostat’s Potential to Protect Kidney Function, with Matthew Weir, MD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Dr. Stein Gold introduces the panel and outlines the discussion’s focus on emerging therapies and evolving clinical approaches in psoriasis and PsA management.

Video Series

Simplifying the Treatment Decisions for Providers and Patients 

Joseph Gatti, DMSc, MPAS, MBA, PA-C, is the founder of the Clinic for Dermatology & Wellness, LLC, and Pure Medspa, LLC. 

This discussion at the SDPA Fall Conference highlights some scheduling and contract essentials for early career success among physician associates (PAs).

Essentials for Early Career Success Among Dermatology PAs, With Joseph Gatti, DMSc, MPAS, MBA, PA-C

Linda Stein Gold, MD, introduces the panel and outlines the discussion’s focus on emerging therapies and evolving clinical approaches in psoriasis and PsA management.

Initial Diagnostic Workup for Patients Presenting With Psoriasis Symptoms 

Andreas Kremer, MD, PhD, MHBA, is the head of hepatology at University Hospital Zurich in Switzerland.

GLISTEN AASLD-presented data show linerixibat reduces biomarkers and itch in PBC, supporting the drug as an ileal bile acid transporter inhibitor.


Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

GLISTEN: Linerixibat Improves Biomarkers and Itch in Patients With PBC, With Andreas Kremer, MD, PhD, MHBA

Harrison Nguyen, MD, MBA, MPH, is a double board-certified dermatologist/Mohs micrographic surgeon and clinical researcher in Houston, Texas.

In this interview with Nguyen, Nguyen highlights takeaways from From 'Basement Membrane to Bedside: The Science & Strategy of Bullous Diseases.'

Discussing Treatment Strategies for Blistering Disorders, With Harrison Nguyen, MD, MBA, MPH

Pavel Strnad, MD, is a full professor and leading physician at the University Hospital Aachen in Germany.

Strnad emphasizes the promise offered by RNA therapeutics in liver disease and what potential fazirsiran may hold for AATD liver disease in a broad spectrum of patients.

Alpha-1 antitrypsin deficiency

Fazirsiran and the Future of RNA Therapy in AATD Liver Disease, With Pavel Strnad, MD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

COPD management evolves with targeted biologic therapies, enhancing treatment precision and improving patient outcomes in respiratory care.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Personalized COPD Treatment: Lessons from Biologic Trials and Clinical Practice

Panelists discuss how both oral agents exhibit reassuring long-term safety and tolerability that support continued use in diverse psoriasis populations.

A Closer Look at Safety and Tolerability for Deucravacitinib and Apremilast in Psoriasis

Panelists discuss how deucravacitinib provides greater scalp and high-impact site clearance than apremilast, supporting more personalized psoriasis care.

Latest News

Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD

Discussing Findings on Secukinumab (Cosentyx) Efficacy Over 4 Years in HS, With Martina Porter, MD

Povetacicept Data Validate APRIL/BAFF Inhibition in IgAN and pMN, With James Tumlin, MD

Tapinarof Shows Early, Sustained Benefits in Pediatric Atopic Dermatitis, With Druhan Howell, MD

IMPACT: Pemvidutide for MASH Resolution and Weight Loss, With Mazen Noureddin, MD, MHSc